Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib

Roginolisib (IOA-244) is a novel, non-ATP competitive phosphoinositide-3-kinase (PI3K) delta inhibitor that regulates Akt/mTOR signaling. Roginolisib was administered once daily to rats and dogs in dose-range finding (DRF) and 4-week GLP toxicology studies. Free plasma levels of roginolisib exceeded...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Veen, Lars, Schmitt, Michael, Deken, Marcel A., Lahn, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629260/
https://www.ncbi.nlm.nih.gov/pubmed/37667445
http://dx.doi.org/10.1177/10915818231200419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629260/
https://www.ncbi.nlm.nih.gov/pubmed/37667445
http://dx.doi.org/10.1177/10915818231200419

Ejemplares similares